Abstract
Causative agents of infectious disease that are multidrug resistant bacterial pathogens represent a serious public health concern due to the increasingly difficult nature of achieving efficacious clinical treatments. Of the various acquired and intrinsic antimicrobial agent resistance determinants, integral-membrane multidrug efflux pumps of the major facilitator superfamily constitute a major mechanism of bacterial resistance. The major facilitator superfamily (MFS) encompasses thousands of known related secondary active and passive solute transporters, including multidrug efflux pumps, from bacteria to humans. This review article addresses recent developments involving the targeting by various modulators of bacterial multidrug efflux pumps from the major facilitator superfamily. It is currently of tremendous interest to modulate bacterial multidrug efflux pumps in order to eventually restore the clinical efficacy of therapeutic agents against recalcitrant bacterial infections. Such MFS multidrug efflux pumps are good targets for modulation.
Keywords: Antimicrobial agents, bacterial pathogens, drug targets, efflux pump modulation, infection, major facilitator superfamily, multidrug resistance.
Infectious Disorders - Drug Targets
Title:Bacterial Multidrug Efflux Pumps of the Major Facilitator Superfamily as Targets for Modulation
Volume: 16 Issue: 1
Author(s): Sanath Kumar, Guixin He, Prathusha Kakarla, Ugina Shrestha, Ranjana KC, Indrika Ranaweera, T. Mark Willmon, Sharla R. Barr, Alberto J. Hernandez and Manuel F. Varela
Affiliation:
Keywords: Antimicrobial agents, bacterial pathogens, drug targets, efflux pump modulation, infection, major facilitator superfamily, multidrug resistance.
Abstract: Causative agents of infectious disease that are multidrug resistant bacterial pathogens represent a serious public health concern due to the increasingly difficult nature of achieving efficacious clinical treatments. Of the various acquired and intrinsic antimicrobial agent resistance determinants, integral-membrane multidrug efflux pumps of the major facilitator superfamily constitute a major mechanism of bacterial resistance. The major facilitator superfamily (MFS) encompasses thousands of known related secondary active and passive solute transporters, including multidrug efflux pumps, from bacteria to humans. This review article addresses recent developments involving the targeting by various modulators of bacterial multidrug efflux pumps from the major facilitator superfamily. It is currently of tremendous interest to modulate bacterial multidrug efflux pumps in order to eventually restore the clinical efficacy of therapeutic agents against recalcitrant bacterial infections. Such MFS multidrug efflux pumps are good targets for modulation.
Export Options
About this article
Cite this article as:
Kumar Sanath, He Guixin, Kakarla Prathusha, Shrestha Ugina, KC Ranjana, Ranaweera Indrika, Mark Willmon T., R. Barr Sharla, J. Hernandez Alberto and F. Varela Manuel, Bacterial Multidrug Efflux Pumps of the Major Facilitator Superfamily as Targets for Modulation, Infectious Disorders - Drug Targets 2016; 16 (1) . https://dx.doi.org/10.2174/1871526516666160407113848
DOI https://dx.doi.org/10.2174/1871526516666160407113848 |
Print ISSN 1871-5265 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3989 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Structure and Functions of P-Glycoprotein
Current Medicinal Chemistry Experimental Developments and Review of Recent Patents for the Repair of Skeletal Muscles by Methods of Regenerative Medicine
Recent Patents on Regenerative Medicine Variability in Individual Responsiveness to Aspirin: Clinical Implications and Treatment
Cardiovascular & Hematological Disorders-Drug Targets Magnetic Resonance Imaging Findings of Sixth Cranial Nerve Palsies in Patients Presenting with Diplopia
Current Medical Imaging The Role of Redox Dysregulation in the Inflammatory Response to Acute Myocardial Ischaemia-reperfusion Injury - Adding Fuel to the Fire
Current Medicinal Chemistry Multiple Roles of the Extracellular Matrix in Inflammation
Current Pharmaceutical Design Adenosine A2A Receptor Antagonists and Parkinsons Disease: State of the Art and Future Directions
Current Pharmaceutical Design Treatment of Epileptic Encephalopathies
Current Pharmaceutical Design CFTR Regulation of Aquaporin-Mediated Water Transport: A Target in Male Fertility
Current Drug Targets Affinity Chromatography Method for Determination of Binding of Drugs to Melanin and Evaluation of Side Effect Potential of Antipsychotic Agents
Current Pharmaceutical Analysis Transcranial Direct Current Stimulation for the Treatment of Refractory Symptoms of Schizophrenia. Current Evidence and Future Directions
Current Pharmaceutical Design The Therapeutic use of the Zonulin Inhibitor AT-1001 (Larazotide) for a Variety of Acute and Chronic Inflammatory Diseases
Current Medicinal Chemistry Recent Progress in the Development of Agonists and Antagonists for Melatonin Receptors
Current Medicinal Chemistry GSK3 at the Edge: Regulation of Developmental Specification and Cell Polarization
Current Drug Targets Possible Exploitation of Non-Neuronal and Non-Chemical Synaptic Signalling Pathways in Epilepsy Therapy
Current Signal Transduction Therapy Mass Spectrometric Imaging of the Nervous System
Current Pharmaceutical Design Sepsis-induced Cardiomyopathy
Current Cardiology Reviews Impact of Dysfunctional Protein Catabolism on Macrophage Cholesterol Handling
Current Medicinal Chemistry Oxidative Stress and Neurodegenerative Diseases: Looking for a Therapeutic Solution Inspired on Benzopyran Chemistry
Current Topics in Medicinal Chemistry RING-, HECT-, and RBR-type E3 Ubiquitin Ligases: Involvement in Human Cancer
Current Cancer Drug Targets